Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases
Medication-related osteonecrosis of the jaw (ONJ) is caused by antiresorptive (bisphosphonates and denosumab) and antiangiogenic agents, with the first report of denosumab-related ONJ emerging in 2010. To date, although certain case reports on denosumab-related ONJ have been published, those of ONJ...
Gespeichert in:
| Veröffentlicht in: | Molecular and clinical oncology 2016-02, Vol.4 (2), p.191-194 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 194 |
|---|---|
| container_issue | 2 |
| container_start_page | 191 |
| container_title | Molecular and clinical oncology |
| container_volume | 4 |
| creator | MATSUSHITA, YUKI HAYASHIDA, SAKI MORISHITA, KOTA SAKAMOTO, HIROSHI NARUSE, TOMOFUMI SAKAMOTO, YUKI YAMADA, SHIN-ICHI YANAMOTO, SOUICHI FUJITA, SHUICHI IKEDA, TOHRU UMEDA, MASAHIRO |
| description | Medication-related osteonecrosis of the jaw (ONJ) is caused by antiresorptive (bisphosphonates and denosumab) and antiangiogenic agents, with the first report of denosumab-related ONJ emerging in 2010. To date, although certain case reports on denosumab-related ONJ have been published, those of ONJ caused by a single application of the drug are scarce. In addition, only one report described the histopathological features of this condition, although not completely; only the sequestrum resected by conservative surgery was evaluated. Although conservative treatment is recommended, the effectiveness of extensive surgery in the early stages of bisphosphonate-related ONJ has been described in recent years. Here we report the clinical and histopathological features of denosumab-related ONJ caused by single application of the drug, which was treated by extensive surgery in two patients. Histopathological analysis revealed a decreased number of osteoclasts in viable bone around the sequestrum, and these appeared morphologically immature, as indicated by the presence of very few nuclei. These findings are different from those for bisphosphonate-related ONJ and may assist in elucidating the mechanism underlying denosumab-related ONJ. Furthermore, extensive surgery may be effective for the management of this condition. |
| doi_str_mv | 10.3892/mco.2015.696 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4734225</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A444309514</galeid><sourcerecordid>A444309514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-6c13d3cdc301c3e5eeeedff091c6af90c5ea35dc1a65c124a5e1dafeb32a40fe3</originalsourceid><addsrcrecordid>eNptkstv1DAQxiMEolXpjTOyBAcOzeJnuuZQqdrykorKAc7WrD3e9SqJl9ih4spfjkPKQhGeg63xbz4_5quqp4wuxFLzV52NC06ZWjS6eVAdcyp1rWWjHx7Wih5VpyntaBn6nHKlH1dHvFlqsVT6uPpxhX1MYwfrGlKKNkBGR2LKGHu0Q0whkehJ3iLZwS0B79HmNAO2hZSJj0MHOcSeQO-IC4UYsM_hV-41-QR5G9u4CRZa4hHyOOAseRuJhYTpSfXIQ5vw9G4-qb68ffN59b6-vnn3YXV5XVtFZa4by4QT1llBmRWosAznPdXMNuA1tQpBKGcZNMoyLkEhc-BxLThI6lGcVBez7n5cd-hsueQArdkPoYPhu4kQzP2dPmzNJn4z8lxIzlUReHknMMSvI6ZsupAsti30GMdk2JI3jWqo0gV9_g-6i-PQl-cZpgWXivEl-0NtoEUTeh_LuXYSNZdSSkG1YrJQi_9QJRx2wZY2-VDy9wrO5oKpf2lAf3gjo2ayjSm2MZNtTLFNwZ_9_S8H-LdJCvBiBtK-tDi4mA7Mx9VNTUtMOj8BYcnNZA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932451281</pqid></control><display><type>article</type><title>Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>MATSUSHITA, YUKI ; HAYASHIDA, SAKI ; MORISHITA, KOTA ; SAKAMOTO, HIROSHI ; NARUSE, TOMOFUMI ; SAKAMOTO, YUKI ; YAMADA, SHIN-ICHI ; YANAMOTO, SOUICHI ; FUJITA, SHUICHI ; IKEDA, TOHRU ; UMEDA, MASAHIRO</creator><creatorcontrib>MATSUSHITA, YUKI ; HAYASHIDA, SAKI ; MORISHITA, KOTA ; SAKAMOTO, HIROSHI ; NARUSE, TOMOFUMI ; SAKAMOTO, YUKI ; YAMADA, SHIN-ICHI ; YANAMOTO, SOUICHI ; FUJITA, SHUICHI ; IKEDA, TOHRU ; UMEDA, MASAHIRO</creatorcontrib><description>Medication-related osteonecrosis of the jaw (ONJ) is caused by antiresorptive (bisphosphonates and denosumab) and antiangiogenic agents, with the first report of denosumab-related ONJ emerging in 2010. To date, although certain case reports on denosumab-related ONJ have been published, those of ONJ caused by a single application of the drug are scarce. In addition, only one report described the histopathological features of this condition, although not completely; only the sequestrum resected by conservative surgery was evaluated. Although conservative treatment is recommended, the effectiveness of extensive surgery in the early stages of bisphosphonate-related ONJ has been described in recent years. Here we report the clinical and histopathological features of denosumab-related ONJ caused by single application of the drug, which was treated by extensive surgery in two patients. Histopathological analysis revealed a decreased number of osteoclasts in viable bone around the sequestrum, and these appeared morphologically immature, as indicated by the presence of very few nuclei. These findings are different from those for bisphosphonate-related ONJ and may assist in elucidating the mechanism underlying denosumab-related ONJ. Furthermore, extensive surgery may be effective for the management of this condition.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2015.696</identifier><identifier>PMID: 26893859</identifier><language>eng</language><publisher>England: D.A. Spandidos</publisher><subject>Analysis ; bisphosphonate osteonecrosis ; Bones ; Cancer ; cathepsin K ; Cathepsins ; Denosumab ; Hospitals ; Immunotherapy ; Medical prognosis ; medication-related osteonecrosis of the jaw ; Metabolism ; Metastasis ; Monoclonal antibodies ; Necrosis ; Oncology ; osteoclasts ; osteocytes ; Patients ; Surgery ; Targeted cancer therapy</subject><ispartof>Molecular and clinical oncology, 2016-02, Vol.4 (2), p.191-194</ispartof><rights>Copyright © 2016, Spandidos Publications</rights><rights>COPYRIGHT 2016 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2016</rights><rights>Copyright © 2016, Spandidos Publications 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-6c13d3cdc301c3e5eeeedff091c6af90c5ea35dc1a65c124a5e1dafeb32a40fe3</citedby><cites>FETCH-LOGICAL-c504t-6c13d3cdc301c3e5eeeedff091c6af90c5ea35dc1a65c124a5e1dafeb32a40fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734225/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734225/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,5556,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26893859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MATSUSHITA, YUKI</creatorcontrib><creatorcontrib>HAYASHIDA, SAKI</creatorcontrib><creatorcontrib>MORISHITA, KOTA</creatorcontrib><creatorcontrib>SAKAMOTO, HIROSHI</creatorcontrib><creatorcontrib>NARUSE, TOMOFUMI</creatorcontrib><creatorcontrib>SAKAMOTO, YUKI</creatorcontrib><creatorcontrib>YAMADA, SHIN-ICHI</creatorcontrib><creatorcontrib>YANAMOTO, SOUICHI</creatorcontrib><creatorcontrib>FUJITA, SHUICHI</creatorcontrib><creatorcontrib>IKEDA, TOHRU</creatorcontrib><creatorcontrib>UMEDA, MASAHIRO</creatorcontrib><title>Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>Medication-related osteonecrosis of the jaw (ONJ) is caused by antiresorptive (bisphosphonates and denosumab) and antiangiogenic agents, with the first report of denosumab-related ONJ emerging in 2010. To date, although certain case reports on denosumab-related ONJ have been published, those of ONJ caused by a single application of the drug are scarce. In addition, only one report described the histopathological features of this condition, although not completely; only the sequestrum resected by conservative surgery was evaluated. Although conservative treatment is recommended, the effectiveness of extensive surgery in the early stages of bisphosphonate-related ONJ has been described in recent years. Here we report the clinical and histopathological features of denosumab-related ONJ caused by single application of the drug, which was treated by extensive surgery in two patients. Histopathological analysis revealed a decreased number of osteoclasts in viable bone around the sequestrum, and these appeared morphologically immature, as indicated by the presence of very few nuclei. These findings are different from those for bisphosphonate-related ONJ and may assist in elucidating the mechanism underlying denosumab-related ONJ. Furthermore, extensive surgery may be effective for the management of this condition.</description><subject>Analysis</subject><subject>bisphosphonate osteonecrosis</subject><subject>Bones</subject><subject>Cancer</subject><subject>cathepsin K</subject><subject>Cathepsins</subject><subject>Denosumab</subject><subject>Hospitals</subject><subject>Immunotherapy</subject><subject>Medical prognosis</subject><subject>medication-related osteonecrosis of the jaw</subject><subject>Metabolism</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Necrosis</subject><subject>Oncology</subject><subject>osteoclasts</subject><subject>osteocytes</subject><subject>Patients</subject><subject>Surgery</subject><subject>Targeted cancer therapy</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkstv1DAQxiMEolXpjTOyBAcOzeJnuuZQqdrykorKAc7WrD3e9SqJl9ih4spfjkPKQhGeg63xbz4_5quqp4wuxFLzV52NC06ZWjS6eVAdcyp1rWWjHx7Wih5VpyntaBn6nHKlH1dHvFlqsVT6uPpxhX1MYwfrGlKKNkBGR2LKGHu0Q0whkehJ3iLZwS0B79HmNAO2hZSJj0MHOcSeQO-IC4UYsM_hV-41-QR5G9u4CRZa4hHyOOAseRuJhYTpSfXIQ5vw9G4-qb68ffN59b6-vnn3YXV5XVtFZa4by4QT1llBmRWosAznPdXMNuA1tQpBKGcZNMoyLkEhc-BxLThI6lGcVBez7n5cd-hsueQArdkPoYPhu4kQzP2dPmzNJn4z8lxIzlUReHknMMSvI6ZsupAsti30GMdk2JI3jWqo0gV9_g-6i-PQl-cZpgWXivEl-0NtoEUTeh_LuXYSNZdSSkG1YrJQi_9QJRx2wZY2-VDy9wrO5oKpf2lAf3gjo2ayjSm2MZNtTLFNwZ_9_S8H-LdJCvBiBtK-tDi4mA7Mx9VNTUtMOj8BYcnNZA</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>MATSUSHITA, YUKI</creator><creator>HAYASHIDA, SAKI</creator><creator>MORISHITA, KOTA</creator><creator>SAKAMOTO, HIROSHI</creator><creator>NARUSE, TOMOFUMI</creator><creator>SAKAMOTO, YUKI</creator><creator>YAMADA, SHIN-ICHI</creator><creator>YANAMOTO, SOUICHI</creator><creator>FUJITA, SHUICHI</creator><creator>IKEDA, TOHRU</creator><creator>UMEDA, MASAHIRO</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160201</creationdate><title>Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases</title><author>MATSUSHITA, YUKI ; HAYASHIDA, SAKI ; MORISHITA, KOTA ; SAKAMOTO, HIROSHI ; NARUSE, TOMOFUMI ; SAKAMOTO, YUKI ; YAMADA, SHIN-ICHI ; YANAMOTO, SOUICHI ; FUJITA, SHUICHI ; IKEDA, TOHRU ; UMEDA, MASAHIRO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-6c13d3cdc301c3e5eeeedff091c6af90c5ea35dc1a65c124a5e1dafeb32a40fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>bisphosphonate osteonecrosis</topic><topic>Bones</topic><topic>Cancer</topic><topic>cathepsin K</topic><topic>Cathepsins</topic><topic>Denosumab</topic><topic>Hospitals</topic><topic>Immunotherapy</topic><topic>Medical prognosis</topic><topic>medication-related osteonecrosis of the jaw</topic><topic>Metabolism</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Necrosis</topic><topic>Oncology</topic><topic>osteoclasts</topic><topic>osteocytes</topic><topic>Patients</topic><topic>Surgery</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MATSUSHITA, YUKI</creatorcontrib><creatorcontrib>HAYASHIDA, SAKI</creatorcontrib><creatorcontrib>MORISHITA, KOTA</creatorcontrib><creatorcontrib>SAKAMOTO, HIROSHI</creatorcontrib><creatorcontrib>NARUSE, TOMOFUMI</creatorcontrib><creatorcontrib>SAKAMOTO, YUKI</creatorcontrib><creatorcontrib>YAMADA, SHIN-ICHI</creatorcontrib><creatorcontrib>YANAMOTO, SOUICHI</creatorcontrib><creatorcontrib>FUJITA, SHUICHI</creatorcontrib><creatorcontrib>IKEDA, TOHRU</creatorcontrib><creatorcontrib>UMEDA, MASAHIRO</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MATSUSHITA, YUKI</au><au>HAYASHIDA, SAKI</au><au>MORISHITA, KOTA</au><au>SAKAMOTO, HIROSHI</au><au>NARUSE, TOMOFUMI</au><au>SAKAMOTO, YUKI</au><au>YAMADA, SHIN-ICHI</au><au>YANAMOTO, SOUICHI</au><au>FUJITA, SHUICHI</au><au>IKEDA, TOHRU</au><au>UMEDA, MASAHIRO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>4</volume><issue>2</issue><spage>191</spage><epage>194</epage><pages>191-194</pages><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>Medication-related osteonecrosis of the jaw (ONJ) is caused by antiresorptive (bisphosphonates and denosumab) and antiangiogenic agents, with the first report of denosumab-related ONJ emerging in 2010. To date, although certain case reports on denosumab-related ONJ have been published, those of ONJ caused by a single application of the drug are scarce. In addition, only one report described the histopathological features of this condition, although not completely; only the sequestrum resected by conservative surgery was evaluated. Although conservative treatment is recommended, the effectiveness of extensive surgery in the early stages of bisphosphonate-related ONJ has been described in recent years. Here we report the clinical and histopathological features of denosumab-related ONJ caused by single application of the drug, which was treated by extensive surgery in two patients. Histopathological analysis revealed a decreased number of osteoclasts in viable bone around the sequestrum, and these appeared morphologically immature, as indicated by the presence of very few nuclei. These findings are different from those for bisphosphonate-related ONJ and may assist in elucidating the mechanism underlying denosumab-related ONJ. Furthermore, extensive surgery may be effective for the management of this condition.</abstract><cop>England</cop><pub>D.A. Spandidos</pub><pmid>26893859</pmid><doi>10.3892/mco.2015.696</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2049-9450 |
| ispartof | Molecular and clinical oncology, 2016-02, Vol.4 (2), p.191-194 |
| issn | 2049-9450 2049-9469 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4734225 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Analysis bisphosphonate osteonecrosis Bones Cancer cathepsin K Cathepsins Denosumab Hospitals Immunotherapy Medical prognosis medication-related osteonecrosis of the jaw Metabolism Metastasis Monoclonal antibodies Necrosis Oncology osteoclasts osteocytes Patients Surgery Targeted cancer therapy |
| title | Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T00%3A54%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Denosumab-associated%20osteonecrosis%20of%20the%20jaw%20affects%20osteoclast%20formation%20and%20differentiation:%20Pathological%20features%20of%20two%20cases&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=MATSUSHITA,%20YUKI&rft.date=2016-02-01&rft.volume=4&rft.issue=2&rft.spage=191&rft.epage=194&rft.pages=191-194&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2015.696&rft_dat=%3Cgale_pubme%3EA444309514%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932451281&rft_id=info:pmid/26893859&rft_galeid=A444309514&rfr_iscdi=true |